The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
💡 한 문장 핵심
양성 전립선 비대증에서 terazosin, finasteride 또는 병용 요법의 효능. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
5/5 보강
TL;DR
In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazOSin and finasterside was no more effective than terazoshin alone.
📑 코퍼스 인용 관계
· 인용됨 12
📑 인용한 논문 (6) ▾
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Niger… Nigerian journal of surgery : official publication of the Nigerian Surgical Research Society · 2017
- [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescri… Der Urologe. Ausg. A · 2017
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A S… The Journal of clinical and aesthetic dermatology · 2016
- Finasteride for benign prostatic hyperplasia. The Cochrane database of systematic reviews · 2010
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Therapeutics and clinical risk management · 2009
연도별 인용 (2012–2026) · 합계 192
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Hormonal and reproductive studies
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
양성 전립선비대증(benign prostatic hyperplasia, BPH) 치료에서 전립선 평활근을 이완시키는 알파1-차단제(terazosin)와 조직 내 안드로겐을 감소시키는 5알파-환원효소 억제제(finasteride)의 효능을 단독 및 병용으로 비교하고자 했습니다.
【방법】
BPH 남성 1,229명을 위약, terazosin(10mg/일), finasteride(5mg/일), 두 약물 병용 4군으로 나눠 1년간 추적했고, 미국비뇨기과학회 증상점수(AUA symptom score)와 최대요속(peak urinary-flow rate)을 기저치 및 주기적으로 측정했습니다.
【주요 결과】
1년 후 증상점수는 위약 -2.6, finasteride -3.2, terazosin -6.1, 병용 -6.2점 감소했고, 최대요속은 각각 1.4, 1.6, 2.7, 3.2ml/초 증가했습니다(terazosin·병용군이 finasteride·위약 대비 P<0.001). Finasteride는 위약과 차이가 없었으며, 병용요법도 terazosin 단독보다 우수하지 않았습니다.
【임상적 시사점 (성형외과 의사 관점)】
이 논문은 비뇨기과 영역으로 성형외과 시술과 직접 관련은 없으나, 약물 기전 비교 연구의 모범 사례로 참고할 수 있습니다. 다만 중장년 남성 환자 상담 시 BPH 동반 가능성과 복용 약물(특히 알파차단제)을 확인하는 것은 의미가 있는데, terazosin 같은 알파1-차단제는 국소마취제 병용이나 수술 중 혈압 변동(기립성 저혈압) 위험과 관련될 수 있어 수술 전 문진에 활용할 수 있습니다.
[BACKGROUND] Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.
[METHODS] We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.
[RESULTS] The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1.6, 2.7, and 3.2 ml per second, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). Finasteride had no more effect on either measure than placebo. In the placebo group, 1.6 percent of the men discontinued the study because of adverse effects, as did 4.8 to 7.8 percent of the men in the other three groups.
[CONCLUSIONS] In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazosin and finasteride was no more effective than terazosin alone.
[METHODS] We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.
[RESULTS] The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1.6, 2.7, and 3.2 ml per second, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). Finasteride had no more effect on either measure than placebo. In the placebo group, 1.6 percent of the men discontinued the study because of adverse effects, as did 4.8 to 7.8 percent of the men in the other three groups.
[CONCLUSIONS] In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazosin and finasteride was no more effective than terazosin alone.
- p-value P<0.001
【연구 목적】 양성 전립선비대증(benign prostatic hyperplasia, BPH) 치료에서 전립선 평활근을 이완시키는 알파1-차단제(terazosin)와 조직 내 안드로겐을 감소시키는 5알파-환원효소 억제제(finasteride)의 효능을 단독 및 병용으로 비교하고자 했습니다.
APA 7
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group.. The New England journal of medicine, 335(8), 533-9. https://doi.org/10.1056/NEJM199608223350801
Vancouver
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New Engl. jour. medi.. 1996;335(8):533-9. doi:10.1056/NEJM199608223350801
AMA 11
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New Engl. jour. medi.. 1996;335(8):533-9. doi:10.1056/NEJM199608223350801
Chicago
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., and Padley, R. J.. 1996. "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group." The New England journal of medicine 335 (8): 533-9. https://doi.org/10.1056/NEJM199608223350801
MLA 9
Lepor, H., et al. "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group." The New England journal of medicine, vol. 335, no. 8, 1996, pp. 533-9. doi:10.1056/NEJM199608223350801.
PMID
8684407 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 12
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- Finasteride for benign prostatic hyperplasia.
- Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of random…
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Comparison of clinical trials with finasteride and dutasteride.
- Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
- A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
- Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic h…
- The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen…
- SRD5A2 and emerging therapies in androgen-driven disorders.
- [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data…
- Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men wi…
같은 제1저자의 인용 많은 논문 (5)
- The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
- The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
- Factors predicting sexual function dissatisfaction following primary partial gland cryoablation.
- Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
- Functional, oncological, regret and complications following partial gland cryo-ablation for low-risk prostate cancer associated with MPMRI targets.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.